Data about the links between Coronavirus disease 2019(COVID-19) and the safety of bloodproducts during the pandemic is inadequate. During the COVID-19 pandemic, high volumes ofpatients receiving blood products due to post-terminal surgical complications depletedstores for the entire hospital, resulting in surgeons unable to acquire emergent bloodproducts. Data from this study can be used to develop a policy on how to handle bloodshortage issues during this and future pandemics. Also, this data can be used todetermine future policies on use of blood products from COVID-19-positive donors.
- To identify the circumstances associated with observed delays in receiving blood
products to use in emergent cases.
- Determine the cost/benefit of moribund patients receiving massive transfusion during
the COVID-19 pandemic.
- Quantify COVID-19 diagnosis and complications in patients arriving with no
indication of disease at index admission as relative to in hospital or blood product
exposure.
Other: Document delays and frequencies of inadequate blood products for emergent cases
The COVID-19 pandemic is contributing to delays in blood product acquisition and
inadequate blood product supplies for emergent cases in hospitals
Inclusion Criteria:
>_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)
Exclusion Criteria:
<18 years of age Prisoners Pregnant women
Methodist Dallas Medical Center- Clinical Research Institute
Dallas, Texas, United States
Jennifer Burris, Pharm D, Principal Investigator
Methodist Health System